Total Knee Arthroplasty, Venous Insufficiency of Leg
Conditions
Keywords
Total knee arthroplasty, lower extremity swelling, inflammation, venous insufficiency, pain management
Brief summary
The goal of this clinical trial is to find out the efficacy of diosmin and hesperidin on postoperative early rehabilitation after primary total knee arthroplasty. The main questions it aims to answer are: Does diosmin and hesperidin combined drug decreases the lower extremity swelling, pain and increases the range of motion after primary total knee arthroplasty surgery compared to standard therapy group? Does diosmin and hesperidin combined drug decreases inflammation after total knee arthroplasty surgery. Participants will take diosmin and hesperidin in addition to standard therapy for 14 days after total knee arthroplasty surgery. Lower extremity swelling, pain and range of motion of the patients will be recorded in every visit.
Interventions
Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
Sponsors
Ankara Etlik City Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who underwent unilateral primary total knee replacement surgery * Patients who are functionally ASA 1, ASA 2 or ASA 3.
Exclusion criteria
* Patients \>80 years or \<18 years of age * Patients with liver insufficiency * Patients with allergy to diosmin or hesperidin * Patients which are not capable to communicate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lower extremity swelling | From enrollment to the end of the treatment at 2 weeks | Lower extremity swelling is measured by measuring extremity diameters from 3 points (below patella, patella and above patella) and noted. Then percentage of increment or decrement of diameters is measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Range of motion | From enrollment to the end of the treatment at 2 weeks | Knee range of motion is measured with goniometer. |
| Blood C-reactive protein value as an inflammotory marker | From enrollment to the end of the treatment at 2 weeks | — |
| Blood erythrocyte sedimentation rate as an inflammotory marker | From enrollment to the end of the treatment at 2 weeks | — |
| Pain | From enrollment to the end of the treatment at 2 weeks | The Visual Analog Scale is used to describe patients' pain. It is a scale that describes pain by giving numbers from 0 to 10. 0 means no pain and 10 means extreme pain. |
| Panimmune value (neutrophil x platelet x monocyte / lymphocyte) as an inflammatory marker | From enrollment to the end of the treatment at 2 weeks | — |
| The systemic immune-inflammation index (neutrophils × platelets/lymphocytes) as an inflammatory marker | From enrollment to the end of the treatment at 2 weeks | — |
| Blood neutrophil/lymphocyte rate as an inflammatory marker | From enrollment to the end of the treatment at 2 weeks | — |
Countries
Turkey (Türkiye)
Outcome results
None listed